XENE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
XENE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
Xenon Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2024 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Mar. 2024.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.
As of today (2024-06-07), Xenon Pharmaceuticals's current stock price is $38.04. Xenon Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.00. Xenon Pharmaceuticals's Cyclically Adjusted PS Ratio of today is .
During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xenon Pharmaceuticals was 22.79. The lowest was 19.84. And the median was 20.92.
The historical data trend for Xenon Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenon Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted Revenue per Share | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Xenon Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Xenon Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?
Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.
We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Xenon Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0 | / | 126.2576 | * | 126.2576 | |
= | 0.000 |
Current CPI (Mar. 2024) = 126.2576.
Xenon Pharmaceuticals Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.539 | 99.473 | 0.684 |
201409 | 0.972 | 99.394 | 1.235 |
201412 | 0.344 | 98.367 | 0.442 |
201503 | 0.282 | 99.789 | 0.357 |
201506 | 0.267 | 100.500 | 0.335 |
201509 | 0.300 | 100.421 | 0.377 |
201512 | 0.225 | 99.947 | 0.284 |
201603 | 0.042 | 101.054 | 0.052 |
201606 | 0.029 | 102.002 | 0.036 |
201609 | 0.027 | 101.765 | 0.033 |
201612 | 0.021 | 101.449 | 0.026 |
201703 | 0.001 | 102.634 | 0.001 |
201706 | 0.001 | 103.029 | 0.001 |
201709 | 0.015 | 103.345 | 0.018 |
201712 | 0.001 | 103.345 | 0.001 |
201803 | 0.000 | 105.004 | 0.000 |
201806 | 0.000 | 105.557 | 0.000 |
201809 | 0.000 | 105.636 | 0.000 |
201812 | 0.000 | 105.399 | 0.000 |
201903 | 0.000 | 106.979 | 0.000 |
201906 | 0.000 | 107.690 | 0.000 |
201909 | 0.136 | 107.611 | 0.160 |
201912 | 0.126 | 107.769 | 0.148 |
202003 | 0.213 | 107.927 | 0.249 |
202006 | 0.383 | 108.401 | 0.446 |
202009 | 0.187 | 108.164 | 0.218 |
202012 | 0.147 | 108.559 | 0.171 |
202103 | 0.118 | 110.298 | 0.135 |
202106 | 0.053 | 111.720 | 0.060 |
202109 | 0.192 | 112.905 | 0.215 |
202112 | 0.070 | 113.774 | 0.078 |
202203 | 0.160 | 117.646 | 0.172 |
202206 | 0.010 | 120.806 | 0.010 |
202209 | 0.002 | 120.648 | 0.002 |
202212 | 0.000 | 120.964 | 0.000 |
202303 | 0.000 | 122.702 | 0.000 |
202306 | 0.000 | 124.203 | 0.000 |
202309 | 0.000 | 125.230 | 0.000 |
202312 | 0.000 | 125.072 | 0.000 |
202403 | 0.000 | 126.258 | 0.000 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.
For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xenon Pharmaceuticals was 22.79. The lowest was 19.84. And the median was 20.92.
Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.
Thank you for viewing the detailed overview of Xenon Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Gary Patou | director | |
Dawn Svoronos | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Gillian Cannon | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Justin D. Gover | director | SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ |
Patrick Machado | director | 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107 |
Elizabeth A. Garofalo | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Steven Gannon | director | C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8 |
Simon N. Pimstone | director | 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8 |
Ian Mortimer | director, officer: PRESIDENT & CEO | C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8 |
Christopher John Kenney | officer: Chief Medical Officer | 200 - 3650 GILMORE WAY, BURNABY, A1 V5G 48W |
Andrea Difabio | officer: Chief Legal Officer | BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451 |
Sherry Aulin | officer: Chief Financial Officer | 200 - 3650 GILMORE WAY, BURNABY A0 V5G 48W |
Sherrington Robin | officer: SVP Bus. & Corp. Development | C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8 |
James R. Empfield | officer: SVP, Drug Discovery | 200 - 3650 GILMORE WAY, BURNABY A1 VG5 48W |
Seggern Christopher Von | officer: Chief Commercial Officer | 200 - 3650 GILMORE WAY, BURNABY A1 V5G 48W |
From GuruFocus
By GuruFocus Research • 05-27-2023
By sperokesalga sperokesalga • 03-22-2023
By Value_Insider Value_Insider • 11-30-2022
By Marketwired • 09-12-2023
By Value_Insider Value_Insider • 11-09-2022
By Marketwired • 10-09-2023
By Marketwired • 08-08-2023
By sperokesalga sperokesalga • 05-02-2023
By Stock market mentor Stock market mentor • 01-04-2023
By sperokesalga sperokesalga • 02-08-2023